Profile data is unavailable for this security.
About the company
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
- Revenue in USD (TTM)683.90k
- Net income in USD-2.79m
- Incorporated2013
- Employees4.00
- LocationProvectus Biopharmaceuticals Inc800 S. Gay Street, Suite 1610KNOXVILLE 37929United StatesUSA
- Phone+1 (865) 769-4011
- Fax+1 (302) 674-5266
- Websitehttps://www.provectusbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anebulo Pharmaceuticals Inc | 0.00 | -8.20m | 42.79m | 2.00 | -- | 11.22 | -- | -- | -0.318 | -0.318 | 0.00 | 0.147 | 0.00 | -- | -- | 0.00 | -104.19 | -- | -113.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 43.13m | 82.00 | -- | 0.5699 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 43.28m | 151.00 | -- | 0.5028 | -- | 0.8296 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 44.14m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Vyne Therapeutics Inc | 493.00k | -33.95m | 44.25m | 10.00 | -- | 0.6965 | -- | 89.77 | -0.8493 | -0.8509 | 0.0124 | 4.31 | 0.0103 | -- | -- | 49,300.00 | -71.12 | -108.41 | -88.91 | -138.57 | -- | -- | -6,885.40 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -24.41m | 45.71m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Rallybio Corp | 598.00k | -66.97m | 46.05m | 25.00 | -- | 0.6503 | -- | 77.01 | -1.59 | -1.59 | 0.0141 | 1.71 | 0.0056 | -- | -- | 13,906.98 | -63.12 | -- | -68.83 | -- | -- | -- | -11,199.50 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Serina Therapeutics Inc | 179.00k | -18.67m | 46.09m | 4.00 | -- | -- | -- | 257.51 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 46.27m | 37.00 | -- | 1.08 | -- | 6.25 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.08m | 46.69m | 5.00 | -- | 8.70 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -12.59m | 47.01m | 14.00 | -- | 2.71 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Xilio Therapeutics Inc | 2.36m | -65.53m | 47.47m | 73.00 | -- | 1.42 | -- | 20.14 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 47.62m | 4.00 | -- | -- | -- | 69.63 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| OncoCyte Corp | 1.02m | -36.80m | 50.51m | 43.00 | -- | 1.77 | -- | 49.37 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Data as of Nov 13 2024. Currency figures normalised to Provectus Biopharmaceuticals Inc's reporting currency: US Dollar USD
0.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Home Federal Bank of Tennessee (Investment Management)as of 30 Sep 2024 | 100.00k | 0.02% |
| Lee, Danner & Bass, Inc.as of 30 Sep 2024 | 50.00k | 0.01% |
| Atlas Wealth LLCas of 30 Jun 2024 | 26.62k | 0.01% |
| LBMC Investment Advisors LLCas of 30 Sep 2024 | 20.00k | 0.01% |
| Academy Capital Management, Inc.as of 30 Sep 2024 | 20.00k | 0.01% |
| Financal Symmetry, Inc.as of 30 Sep 2024 | 10.19k | 0.00% |
| Huntington National Bank (Investment Management)as of 30 Sep 2024 | 1.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
